Refractory vasculitis

Autoimmunity Reviews

Volumn 10, Issue 11, 2011, Pages 702-706

  Rutgers, Abraham ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; Refractory; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER CANCER; BONE MARROW DEPRESSION; CHURG STRAUSS SYNDROME; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; GONADAL DISEASE; GRANULOMATOSIS WITH POLYANGIITIS; HEMORRHAGIC CYSTITIS; HUMAN; KIDNEY GRAFT REJECTION; LEUKOPENIA; LOADING DRUG DOSE; MICROSCOPIC POLYANGIITIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; RECURRENT DISEASE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; RECURRENCE; VASCULITIS;

EID: 80052263871     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.024     Document Type: Review

References (43)

1. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
2. Hellmich B., Flossmann O., Gross W.L., Bacon P., Cohen-Tervaert J.W., Guillevin L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617.
3. Falk R.J., Jennette J.C. ANCA are pathogenic-oh yes they are!. J Am Soc Nephrol 2002, 13:1977-1979.
4. Langford C.A., Hoffman G.S. Rare diseases.3: Wegener's granulomatosis. Thorax 1999, 54:629-637.
5. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
6. Cohen Tervaert J.W., van der Werf T.S.S.C.A., Timens W., Kallenberg C.G. Pulmonary manifestations of systemic vasculitides 1998, 53-85. Birkhauser Verlag, Ref Type: Serial (Book,Monograph). D.A. Isenberg, S.G. Spiro (Eds.).
7. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001, 13:48-55.
8. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68:310-317.
9. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-Suarez L.F., van der Woude F.J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004, 65:1440-1448.
10. de Groot K., Harper L., Jayne D.R., Flores Suarez L.F., Gregorini G., Gross W.L., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150:670-680.
11. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188.
12. de Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469.
13. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
14. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
15. Mauri C. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010, 22:761-767.
16. Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840.
17. Walsh M., Chaudhry A., Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008, 67:1322-1327.
18. Sykes M., Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005, 435:620-627.
19. Matteson E.L., Orces C.H., Duffy J., Lipsky J.J., Pike M.G., Sandborn W.J. Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum 1999, 42:186-187.
20. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361.
21. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
22. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717-721.
23. Morgan M.D., Drayson M.T., Savage C.O., Harper L. Addition of Infliximab to Standard Therapy for ANCA-Associated Vasculitis. Nephron Clin Pract 2011, 117:c89-c97.
24. Karkar A.M., Smith J., Pusey C.D. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 2001, 16:518-524.
25. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731-740.
26. Laurino S., Chaudhry A., Booth A., Conte G., Jayne D. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010, 25:3307-3314.
27. Hiemstra T.F., Jones R.B., Jayne D.R. Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid. Nephron Clin Pract 2010, 116:c1-c10.
28. Hiemstra T.F., Walsh M., Mahr A., Savage C.O., de Groot K., Harper L., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010, 304:2381-2388.
29. Amemiya H., Suzuki S., Ota K., Takahashi K., Sonoda T., Ishibashi M., et al. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990, 49:337-343.
30. Hotta O., Furuta T., Chiba S., Yusa N., Taguma Y. Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis. Am J Kidney Dis 1999, 34:894-901.
31. Ramos-Casals M., Garcia-Hernandez F.J., de Ramon E., Callejas J.L., Martinez-Berriotxoa A., Pallares L., et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476.
32. Jones R.B., Ferraro A.J., Chaudhry A.N., Brogan P., Salama A.D., Smith K.G., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168.
33. Roccatello D., Baldovino S., Alpa M., Rossi D., Napoli F., Naretto C., et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008, 26:S67-S71.
34. Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008, 35:2017-2023.
35. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
36. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006, 45:1432-1436.
37. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180-187.
38. Benenson E., Fries J.W., Heilig B., Pollok M., Rubbert A. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005, 24:251-257.
39. Birck R., Warnatz K., Lorenz H.M., Choi M., Haubitz M., Grunke M., et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003, 14:440-447.
40. Flossmann O., Baslund B., Bruchfeld A., Tervaert J.W., Hall C., Heinzel P., et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009, 68:1125-1130.
41. Stassen P.M., Tervaert J.W., Stegeman C.A. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007, 66:798-802.
42. Statkute L., Oyama Y., Barr W.G., Sufit R., Ho S., Verda L., et al. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis 2008, 67:991-997.
43. Kotter I., Daikeler T., Amberger C., Tyndall A., Kanz L. Autologous stem cell transplantation of treatment-resistant systemic vasculitis-a single center experience and review of the literature. Clin Nephrol 2005, 64:485-489.